Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

NCT00618657 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT00618657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00618657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Lead sponsor
University of California, Irvine
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2008
Completion date
July 31, 2021
Enrollment
127 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-negative breast cancer, her2-positive breast cancer, recurrent breast cancer, stage ia breast cancer, stage ib breast cancer, stage ii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer